KOSAN Biosciences

Kosan Biosciences is a cancer therapeutics company focused on developing a range of anti-cancer drugs through clinical development. Its product KOS-953, an Hsp90 inhibitor, is in Phase III clinical trials. The company’s portfolio also includes KOS-1584, an epothilone anti-cancer product candidate evaluated in a dose-escalation Phase I clinical trial for patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist currently in Phase I clinical trials for the treatment of GERD. Additionally, Kosan Biosciences has developed KOS-2464, a preclinical stage product for cancer.